Acute transverse myelitis
ORPHA:139417DiseaseAdolescent, Adult, Childhood, Elderly, Infancy
Фенотипы (HPO)53
Частый (30–79%)7
HP:0001324Muscle weakness
HP:0002071Abnormality of extrapyramidal motor function
HP:0002922Increased CSF protein concentration
HP:0003474Somatic sensory dysfunction
HP:0012229CSF pleocytosis
HP:0012332Abnormal autonomic nervous system physiology
HP:5000013Anti-GFAP antibody
Периодический (5–29%)45
HP:0000016Urinary retention
HP:0000020Urinary incontinence
HP:0000822Hypertension
HP:0001257Spasticity
HP:0001278Orthostatic hypotension
HP:0001287Meningitis
HP:0001288Gait disturbance
HP:0001347Hyperreflexia
HP:0001945Fever
HP:0002019Constipation
HP:0002138Subarachnoid hemorrhage
HP:0002385Paraparesis
HP:0002493Upper motor neuron dysfunction
HP:0002495Impaired vibratory sensation
HP:0002578Gastroparesis
HP:0002590Paralytic ileus
HP:0002721Immunodeficiency
HP:0002725Systemic lupus erythematosus
HP:0002839Urinary bladder sphincter dysfunction
HP:0002960Autoimmunity
HP:0003401Paresthesia
HP:0003418Back pain
HP:0003484Upper limb muscle weakness
HP:0003487Babinski sign
HP:0004370Abnormality of temperature regulation
HP:0005341Autonomic bladder dysfunction
HP:0007305CNS demyelination
HP:0009053Distal lower limb muscle weakness
HP:0010547Muscle flaccidity
HP:0010550Paraplegia
HP:0010831Impaired proprioception
HP:0010835Dissociated sensory loss
HP:0011967Decreased circulating copper concentration
HP:0011972Hypoglycorrhachia
HP:0012378Fatigue
HP:0012534Dysesthesia
HP:0025615Abscess
HP:0031179Nuchal rigidity
HP:0031691Severe viral infection
HP:0031700Invasive parasitic infection
HP:0031845Abnormal libido
HP:0032271Extrapulmonary tuberculosis
HP:0032283Disseminated nontuberculous mycobacterial infection
HP:0032492Anti-myelin oligodendrocyte glycoprotein antibody positivity
HP:0100502Decreased circulating vitamin B12 concentration
Очень редкий (1–4%)1
HP:0200023Priapism
Эпидемиология3
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 8.6 | United States | Value and class |
| Point prevalence | 1-9 / 100 000 | 7.9 | United States | Value and class |
| Annual incidence | 1-9 / 100 000 | 4.72 | Worldwide | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)